TuHURA Biosciences, Inc.

NASDAQ:HURA

Biotechnology

Healthcare
$1.37 +6.37%

+$0.14 today

Market cap
$87.31M
Beta
0.01
P/E (TTM)
-4.6
EPS (TTM)
-$0.52
52W Low $0.41High $3.90

Volume 0.19M

Average 0.85M

HURA Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

TuHURA Biosciences, Inc.NASDAQ: HURA

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q1 FY2026 selling, general & admin of $2.3M rose 13.9% year over year, ahead of the -47.4% change in trailing-twelve-month selling, general & admin. Over 3 fiscal years it compounded at +11.8% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +95.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.3M+247.1% QoQ
Last fiscal yearDec 2025
$7.58M+95.8% YoY
LTMMar 2026
$3.55M-47.4% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.9%-100.0%-113.9 pp
1 year+95.8%-100.0%-195.8 pp
3-year CAGR+11.8%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
7.58M USD
Year-over-year change
+95.8%
4-year CAGR
+0.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How HURA compares with its peers on the latest reported figures

  • HURA's LTM Mar 2026 selling, general & admin of $3.55M is the lowest of the 9 companies compared; the peer median is $28.45M.
  • Its year-over-year change of -47.4% is the lowest of 9, against a peer median of -16.9%.
  • Over three fiscal years its annual growth of +11.8% compares with a peer median of -9.8%.
HURA Competitors Peer median
Selling, General & Admin for HURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$16.46B +48531.9%-28.7%—
AGENAgenus Inc.LTM Mar 2026$45.53M -35.6%-12.4%36.8%
SEERSeer, Inc.LTM Mar 2026$40.57M -24.5%-6.8%269.8%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$35.34M -27.5%-17.7%3080.9%
IRDOpus Genetics, Inc.LTM Mar 2026$21.57M +8.6%+44.6%180.0%
SPROSpero Therapeutics, Inc.LTM Mar 2026$19.24M -21.8%-16.6%35.1%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$18.46M -7.7%+13.7%—
CGTXCognition Therapeutics, Inc.LTM Mar 2026$10.32M -12.0%-7.1%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$3.55M -47.4%+11.8%—
Peer median (excluding HURA) $28.45M-16.9%-9.8%180.0%

Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue60K60K55K00
Gross Profit(60K)(60K)(55K)00
Gross Margin—————
Research & Development15.17M9.31M2.66M13.34M20.53M
Selling, General & Admin7.45M5.43M5.73M3.87M7.58M
Operating Expenses22.62M14.74M8.4M17.65M31.8M
Depreciation & Amortization60K60K55K116.71K71.27K
EBITDA(21.97M)(14.59M)(8.27M)(17.43M)(29.36M)
EBITDA Margin—————
Operating Income(22.68M)(14.8M)(8.45M)(17.65M)(31.8M)
Operating Margin—————
Interest Income057.35K89.67K361.63K136.23K
Interest Expense629.29K018.69K4.14M625.28K
Other Income / Expenses21K147K131K(4.03M)1.74M
Income Before Tax(22.66M)(14.65M)(8.32M)(21.68M)(30.06M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(22.66M)(14.65M)(8.32M)(21.68M)(30.06M)
Net Margin—————
EPS (Basic)(903.04)(324.48)(11.29)(1.21)(0.63)
EPS (Diluted)(903.04)(324.48)(11.29)(1.21)(0.63)
Weighted Avg Shares27.83K46.29K752.91K18.66M47.93M
Weighted Avg Shares (Diluted)27.83K46.29K752.91K18.66M47.93M

TuHURA Biosciences, Inc.

NASDAQ:HURA

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.